Compare CRDO & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDO | RGEN |
|---|---|---|
| Founded | 2008 | 1981 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7B | 6.6B |
| IPO Year | 2022 | 1995 |
| Metric | CRDO | RGEN |
|---|---|---|
| Price | $246.75 | $163.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $179.62 | $167.67 |
| AVG Volume (30 Days) | ★ 5.3M | 1.3M |
| Earning Date | 06-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 765.52 | 286.96 |
| EPS | ★ 2.51 | 0.24 |
| Revenue | ★ $1,335,116,000.00 | $141,236,000.00 |
| Revenue This Year | $210.92 | $14.30 |
| Revenue Next Year | $57.22 | $14.52 |
| P/E Ratio | ★ $99.56 | $682.92 |
| Revenue Growth | ★ 205.68 | 35.10 |
| 52 Week Low | $86.49 | $100.99 |
| 52 Week High | $308.67 | $175.77 |
| Indicator | CRDO | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 66.63 |
| Support Level | $225.66 | $156.65 |
| Resistance Level | $241.14 | $163.24 |
| Average True Range (ATR) | 18.44 | 8.35 |
| MACD | 2.60 | 1.52 |
| Stochastic Oscillator | 76.81 | 91.22 |
Credo Technology Group Holding Ltd provides connectivity solutions for AI-driven applications, cloud computing, and hyperscale networks. Its high-speed copper and optical interconnect products support data infrastructure demands. The Company's product portfolio includes ZeroFlap (ZF) Active Electrical Cables (AECs), ZF optical transceivers, OmniConnect memory solutions, and retimers and DSPs for optical and copper Ethernet and PCIe, leveraging the PILOT diagnostic and analytics software platform. Its products are based on Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies and include integrated circuits (ICs), Active Electrical Cables (AECs), SerDes Chiplets, and SerDes IP licensing solutions. The United States generates the maximum revenue.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.